X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
PLETHICO PHARMA Fact Sheet, PLETHICO PHARMA Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA Fact Sheet   (PLPL)

Here is the latest financial fact sheet of PLETHICO PHARMA. For more details, see the PLETHICO PHARMA quarterly results and PLETHICO PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

PLETHICO PHARMA Price History

Price Rs 7.9
Mkt Cap Rs m 271
Vol '000 10.4
P/E X -1.1
P/CF X 0.2
EPS (TTM) Rs -7.1
% ch % -4.9
No. of shares m 34.07
% ch week % -4.9
% ch 1-mth % -5.6
% ch 12-mth % -70.2
52 week H/L Rs 36.9/7.6
(As on Jun 13, 2016 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PLETHICO PHARMA Financials

No. of Mths
Year Ending
12
Dec-09
*
12
Dec-10
*
12
Dec-11
*
12
Dec-12
*
15
Mar-14
*
5-Yr Chart
Click to enlarge
PLETHICO PHARMA EQUITY SHARE DATA
High Rs380450395397395 
Low Rs8131233115631 
Sales per share (Unadj.) Rs367.9451.7456.9478.7604.4 
Earnings per share (Unadj.) Rs63.771.730.229.832.5 
Diluted earnings per shareRs63.771.730.229.832.5 
Cash flow per share (Unadj.) Rs68.579.535.435.051.3 
Dividends per share (Unadj.) Rs2.502.50000 
Adj. dividends per shareRs2.502.500.000.000.00 
Dividend yield (eoy) %1.10.7000 
Book value per share (Unadj.) Rs259.7313.4400.5401.1473.6 
Adj. book value per shareRs259.7313.5400.6401.2473.7 
Shares outstanding (eoy) m34.0834.0834.0834.0834.08 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.60.80.80.60.4 
Avg P/E ratio x3.65.312.09.36.6 
P/CF ratio (eoy) x3.44.810.37.94.2 
Price / Book Value ratio x0.91.20.90.70.5 
Dividend payout %3.93.5000 
Avg Mkt Cap Rs m7,85512,98412,3719,4287,262 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,1011,1731,1891,1891,596 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
PLETHICO PHARMA INCOME DATA
Net Sales Rs m12,53815,39315,57016,31520,598 
Other income Rs m-52-201843305386 
Total revenues Rs m12,48515,19316,41416,62020,984 
Gross profit Rs m2,4593,3262,1101,5802,818 
Depreciation Rs m166264176177642 
Interest Rs m3013068356141,593 
Profit before tax Rs m1,9402,5551,9421,093969 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m164137-63000 
Tax Rs m-6624828378-138 
Profit after tax Rs m2,1692,4441,0291,0151,107 
Gross profit margin %19.621.613.69.713.7 
Effective tax rate %-3.49.714.67.1-14.3 
Net profit margin %17.315.96.66.25.4 
PLETHICO PHARMA BALANCE SHEET DATA
Current assets Rs m7,4289,38115,00717,00918,877 
Current liabilities Rs m1,4312,1828,60110,96311,896 
Net working cap to sales %47.846.841.137.133.9 
Current ratio x5.24.31.71.61.6 
Inventory Days Days4037434236 
Debtors Days Days132151228274198 
Net fixed assets Rs m6,1456,6648,4648,2219,861 
Share capital Rs m341341341341341 
"Free" reserves Rs m8,16410,24111,10511,22412,331 
Net worth Rs m8,84910,68213,64913,67016,139 
Long term debt Rs m5,5775,4283,1932,5594,706 
Total assets Rs m15,56118,03425,59527,31733,146 
Interest coverage x7.59.43.32.81.6 
Debt to equity ratio x0.60.50.20.20.3 
Sales to assets ratio x0.80.90.60.60.6 
Return on assets %15.915.27.36.08.1 
Return on equity %24.522.97.57.46.9 
Return on capital %16.718.612.810.512.3 
Exports to sales %24.617.017.619.521.4 
Imports to sales %4.11.16.214.115.2 
Exports (fob) Rs m3,0852,6242,7453,1754,402 
Imports (cif) Rs m5171699602,3063,136 
Fx inflow Rs m3,0852,6242,7453,1754,402 
Fx outflow Rs m7963031,0892,3643,184 
Net fx Rs m2,2892,3201,6568111,219 
PLETHICO PHARMA CASH FLOW
From Operations Rs m 1,654 1,764 -2,717 -610 2,437 
From Investments Rs m -335 -847 -997 75 -6,265 
From Financial Activity Rs m -1,232 -853 3,567 -405 2,490 
Net Cashflow Rs m 88 64 -147 -940 -1,337 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 82.7%
Foreign collaborators 0.0%
Indian inst/Mut Fund 4.3%
FIIs 5.5%
ADR/GDR 0.0%
Free float 7.5%
Shareholders 10,665
Pledged promoter(s) holding 85.7%
 

Company Information

REGD OFF A B Road, Manglia, Indore, Madhya Pradesh - 453 771
E-MAIL companysecretary@plethico.com WEB www.plethico.com
TELEPHONE (0731) 242 2881 FAX (0731) 242 093
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR N. P. Gandhi & Co.
CHM: Shashikant Patel (MD) COMP SEC: Amrish Kumar Chourasia YEAR OF INC: 1991 BSE CODE: 532739 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   LUPIN LTD  INDOCO REMEDIES  GSK PHARMA  TORRENT PHARMA  PANACEA BIOTECH  

Compare PLETHICO PHARMA With:   LUPIN LTD  INDOCO REMEDIES  GSK PHARMA  TORRENT PHARMA  PANACEA BIOTECH  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak End to the Week; Auto & PSU Stocks Fall(Closing)

Profit booking continued in the afternoon session in the Indian share markets amid weak European cues. At the closing bell, the BSE Sensex stood lower by 153 points.

Views on news

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

More Views on News

Most Popular

Digital Transactions were Growing Faster Before Demonetisation(Vivek Kaul's Diary)

Jun 12, 2017

Which brings us back to the basic question, why was demonetisation carried out?

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Should You Trade In Mutual Funds As You Do In Stocks?(Outside View)

Jun 10, 2017

Trading is not synonymous with mutual funds, PersonalFN explains.

Which Way Will Inflation Go?(Chart Of The Day)

Jun 10, 2017

RBI and government at loggerheads over interest rates.

More

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - ACTAVIS COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS